Alitretinoin is a vitamin A derivative used to treat Kaposi's sarcoma and used off label to treat chronic hand eczema and psoriasis. An important regulator of gene expression during growth and development, and in neoplasms.
- Mechanism
- Curator reviewed
Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells.
- Primary indication
- For topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.Curator reviewed · 4 structured indications
- Formula / weight
- C20H28O2 · 300.4351 g/mol (avg)
- First approval
- Canada, 1999 · United States, 2006
- Also known as
- 9-cis-retinoic acid · 9-cis-Tretinoin · 9(Z)-Retinoic acid
- Code names
- AGN-192013 · ALRT-1057 · BAL-4079 · CCRIS 7098 · LG100057 · LGD1057 · NSC-659772
- Brand names
Resolves to
SHGAZHPCJJPHSC-ZVCIMWCZSA-NSMILESC\C(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(\C)=C\C(O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Alitretinoin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account